Characterization of Endogenous G-CSF and the Inverse Correlation to Chemotherapy-Induced Neutropenia in Patients with Breast Cancer Using Population Modeling
暂无分享,去创建一个
Mats O. Karlsson | Lena E. Friberg | M. Karlsson | H. Lindman | Henrik Lindman | L. Friberg | Angelica L. Quartino | M. Karlsson | A. Quartino
[1] W. Evans,et al. Pharmacokinetics of subcutaneous recombinant human granulocyte colony-stimulating factor in children. , 1992 .
[2] T. Whitsett,et al. Effects of a single, large, intravenous iniection of dexamethasone , 1972, Clinical pharmacology and therapeutics.
[3] J. Bergh,et al. Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients , 2006, Cancer Chemotherapy and Pharmacology.
[4] R. Ramakrishnan,et al. Basic Pharmacodynamic Models for Agents That Alter Production of Natural Cells , 1999, Journal of Pharmacokinetics and Biopharmaceutics.
[5] Mats O Karlsson,et al. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] Lewis B. Sheiner,et al. A population pharmacokinetic model for docetaxel (Taxotere®): Model building and validation , 1996, Journal of Pharmacokinetics and Biopharmaceutics.
[7] M. Fukuda,et al. Levels of recombinant human granulocyte colony-stimulating factor in serum are inversely correlated with circulating neutrophil counts , 1996, Antimicrobial agents and chemotherapy.
[8] Gisela Schwab,et al. Pharmacokinetic/Pharmacodynamic Modeling of Pegfilgrastim in Healthy Subjects , 2006, Journal of clinical pharmacology.
[9] Y. Sawada,et al. Pharmacokinetic/pharmacodynamic analysis of neutrophil proliferation induced by recombinant granulocyte colony-stimulating factor (rhG-CSF): comparison between intravenous and subcutaneous administration. , 1997, Biological & pharmaceutical bulletin.
[10] Bing Wang,et al. Population Pharmacokinetic–Pharmacodynamic Modeling of Filgrastim (r-metHuG-CSF) in Healthy Volunteers , 2001, Journal of Pharmacokinetics and Pharmacodynamics.
[11] W. Jusko,et al. Dose Equivalency Evaluation of Major Corticosteroids: Pharmacokinetics and Cell Trafficking and Cortisol Dynamics , 2003, Journal of clinical pharmacology.
[12] Y. Sugiyama,et al. Kinetic analysis of receptor-mediated endocytosis of G-CSF derivative, nartograstim, in rat bone marrow cells. , 1996, The American journal of physiology.
[13] L. Roskos,et al. Polyethylene glycol modification of filgrastim results in decreased renal clearance of the protein in rats. , 2004, Journal of pharmaceutical sciences.
[14] G. Welzl,et al. Regulated plasma levels of colony‐stimulating factors, interleukin‐6 and interleukin‐10 in patients with acute leukaemia and non‐Hodgkin's lymphoma undergoing cytoreductive chemotherapy , 1996, British journal of haematology.
[15] T. Kumakawa,et al. Levels of serum granulocyte colony-stimulating factor in patients with infections. , 1990, Blood.
[16] Mats O. Karlsson,et al. Use of Prior Information to Stabilize a Population Data Analysis , 2002, Journal of Pharmacokinetics and Pharmacodynamics.
[17] H. Eichler,et al. Glucocorticoids dose-dependently increase plasma levels of granulocyte colony stimulating factor in man. , 1998, The Journal of clinical endocrinology and metabolism.
[18] A. Roberts. G-CSF: A key regulator of neutrophil production, but that's not all! , 2005, Growth factors.
[19] Wojciech Krzyzanski,et al. Population Pharmacokinetic Modelling of Filgrastim in Healthy Adults following Intravenous and Subcutaneous Administrations , 2009, Clinical pharmacokinetics.
[20] Wojciech Krzyzanski,et al. Population Modeling of Filgrastim PK‐PD in Healthy Adults Following Intravenous and Subcutaneous Administrations , 2010, Journal of clinical pharmacology.
[21] M. Piccart,et al. Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] T. Iga,et al. Pharmacokinetic/pharmacodynamic analysis of neutrophil proliferation induced by rhG-CSF in patients receiving antineoplastic drugs. , 2004, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.
[23] L. Hareng,et al. Induction and Regulation of Endogenous Granulocyte Colony-Stimulating Factor Formation , 2002, Biological chemistry.
[24] Mats O Karlsson,et al. Model-based neutrophil-guided dose adaptation in chemotherapy: evaluation of predicted outcome with different types and amounts of information. , 2010, Basic & clinical pharmacology & toxicology.
[25] T. Dexter,et al. The regulation of hemopoietic cell development by the stromal cell environment and diffusible regulatory molecules. , 1984, Progress in clinical and biological research.
[26] Mats O. Karlsson,et al. Mechanistic Models for Myelosuppression , 2003, Investigational New Drugs.
[27] Y. Kato,et al. Increased serum human granulocyte colony-stimulating factor (G-CSF) levels following intravenous infusion of high-dose methylprednisolone. , 1996, Endocrine journal.
[28] Ss Beal,et al. NONMEM User’s Guides. (1989–2009) , 2009 .
[29] S. Higuchi,et al. Pharmacokinetic and Pharmacodynamic Analysis of Subcutaneous Recombinant Human Granulocyte Colony Stimulating Factor (Lenograstim) Administration , 1999, Journal of clinical pharmacology.
[30] I. Trocóniz,et al. Comparison of different semi-mechanistic models for chemotherapy-related neutropenia: application to BI 2536 a Plk-1 inhibitor , 2011, Cancer Chemotherapy and Pharmacology.
[31] Mats O. Karlsson,et al. Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression , 2010, Cancer Chemotherapy and Pharmacology.
[32] L B Sheiner,et al. A population model for the leukopenic effect of etoposide , 1995, Clinical pharmacology and therapeutics.
[33] D. Concordet,et al. Model-Based Approach to Describe G-CSF Effects in Carboplatin-Treated Cancer Patients , 2013, Pharmaceutical Research.
[34] Cockcroft Dw,et al. Prediction of Creatinine Clearance from Serum Creatinine , 1976 .
[35] A. Goldhirsch,et al. Dose–response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer , 1998 .
[36] T. Dexter. Regulation of hemopoietic cell growth and development: experimental and clinical studies. , 1989, Leukemia.
[37] I. Trocóniz,et al. Prediction of Neutropenia‐Related Effects of a New Combination Therapy With the Anticancer Drugs BI 2536 (a Plk1 Inhibitor) and Pemetrexed , 2010, Clinical pharmacology and therapeutics.
[38] Y. Sugiyama,et al. Pharmacokinetics and pharmacodynamics of a recombinant human granulocyte colony-stimulating factor. , 1996, Drug metabolism reviews.
[39] S. Urien,et al. Pharmacokinetic Modelling of 5-FU Production from Capecitabine—A Population Study in 40 Adult Patients with Metastatic Cancer , 2005, Journal of Pharmacokinetics and Pharmacodynamics.
[40] Hitoshi Sato,et al. Population pharmacokinetic and pharmacodynamic analysis for time courses of docetaxel‐induced neutropenia in Japanese cancer patients , 2007, Cancer science.
[41] M. Karlsson,et al. Models of schedule dependent haematological toxicity of 2'-deoxy-2'-methylidenecytidine (DMDC) , 2000, European Journal of Clinical Pharmacology.
[42] M. Marty,et al. Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. , 1993, Cancer research.
[43] G. Lyman,et al. Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. , 2008, Journal of the National Comprehensive Cancer Network : JNCCN.
[44] M. Karlsson,et al. A simultaneous analysis of the time-course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic myelosuppression model , 2012, Investigational New Drugs.
[45] J. Friedberg,et al. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] G. Weiss,et al. Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.